gemcitabine has been researched along with gsk525762a in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Huang, M; Huang, Q; Lin, X; Liu, C; Liu, Z; Meng, F; Wang, C; Xie, F | 1 |
2 other study(ies) available for gemcitabine and gsk525762a
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.
Topics: Animals; Bcl-2-Like Protein 11; Benzodiazepines; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice, Nude; Neoplasm Invasiveness; Xenograft Model Antitumor Assays | 2018 |